INTERACTION OF THE STATE AND PHARMACEUTICAL COMPANIES AS A NEW METHOD OF PPP IN HEALTH CARE OF THE REPUBLIC OF KAZAKHSTAN

Abstract

The purpose of the article is to review the main features of public-private partnership (PPP) in healthcare. To increase the overall degree of drug provision, the author proposes to work towards increasing the overall level of funding, which comes from the state budget; apply insurance medicine for citizens; the most rational and efficient use of funds from the budget; attract a variety of private investments.

It is concluded that currently in Kazakhstan one can observe the formulary system. Patients who have various diseases that seem to be socially significant receive medicines free of charge thanks to the funds allocated from the state budget. In Kazakhstan, the legislation in the field of pharmaceuticals is exactly the same as the European legislation, as well as the experience that is available among Western countries.

The main goal of public-private interaction (PPP) and the creation of schemes on the basis of which the process of risk sharing by companies in the pharmaceutical sector takes place is that additional value is created through the latest medicines. However, it will by no means always correspond to the additional cost that society is ready to pay in a given period of time. Therefore, a huge role is played by regular mechanisms that protect the state systems that exist in the field of health from spending that are unjustified. However, among other things, these costs provide an opportunity for citizens to receive treatment on the terms that will be most beneficial in order to preserve the general health of society.

It has been established that the changes that have affected the legislation of the Republic of Kazakhstan, as well as the use of a completely different format of cooperation with various pharmaceutical companies, will make it possible to conclude various agreements for the implementation of projects aimed at providing patients with access to more innovative drugs; improve the overall degree of diagnostics and development of information and communication technologies (ICT). This will be done by attracting investments that are beneficial to all entities.